Novo Nordisk A/S (NVO) Stock Forecast & Price Target

$44.48 +0.20 (+0.45%)

Closing price 03:59 PM Eastern

Extended Trading

$44.68 +0.20 (+0.45%)

As of 07:59 PM Eastern

Compare

Novo Nordisk A/S - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 21 Analyst Ratings

Sell
2

Hold
14

Buy
5

Based on 21 Wall Street analysts who have issued ratings for Novo Nordisk A/S in the last 12 months, the stock has a consensus rating of "Hold." Out of the 21 analysts, 2 have given a sell rating, 14 have given a hold rating, and 5 have given a buy rating for NVO.

Consensus Price Target

$65.56
47.40% Upside

According to the 21 analysts' twelve-month price targets for Novo Nordisk A/S, the average price target is $65.56. The highest price target for NVO is $175.00, while the lowest price target for NVO is $40.00. The average price target represents a forecasted upside of 47.40% from the current price of $44.48.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for NVO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Novo Nordisk A/S and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NVO Analyst Ratings Over Time

Type	Current Forecast 8/5/25 to 8/5/26	1 Month Ago 7/6/25 to 7/6/26	3 Months Ago 5/7/25 to 5/7/26	1 Year Ago 8/5/24 to 8/5/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	4 Buy rating(s)	2 Buy rating(s)
Hold	14 Hold rating(s)	17 Hold rating(s)	18 Hold rating(s)	8 Hold rating(s)
Sell	2 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$65.56	$65.56	$65.56	$93.67
Forecasted Upside	47.40% Upside	33.04% Upside	43.22% Upside	98.45% Upside
Consensus Rating	Hold	Hold	Hold	Hold

NVO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NVO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Novo Nordisk A/S Stock vs. The Competition

Type	Novo Nordisk A/S	Healthcare Companies	Broader Market
Consensus Rating Score	2.14	2.30	2.52
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	47.40% Upside	913.08% Upside	11.52% Upside
News Sentiment Rating	Neutral News See Recent NVO News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
7/20/2026	Weiss Ratings 5 of 5 stars		Reiterated Rating	Sell (D+)
7/20/2026	Citigroup 4 of 5 stars		Reiterated Rating	Neutral
7/13/2026	Zacks Research Not Rated		Downgrade	Hold ➝ Strong Sell
7/6/2026	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold
6/19/2026	Nordea Equity Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Buy
3/26/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Peer Perform
3/18/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Outperform	$175.00	+367.93%
3/10/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold	$42.00	+5.60%
3/3/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Thibault Boutherin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$40.00	+5.99%
3/2/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	James Quigley Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$63.00 ➝ $41.00	+9.34%
A letter from Shannon Stansberry (Ad) Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. Watch the full story and see the verified track record for yourself
2/24/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Vosser Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
2/24/2026	Kepler Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold
2/23/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold
2/12/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Leuchten Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Underperform ➝ Hold
2/5/2026	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Evan Seigerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Market Perform
1/9/2026	CICC Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Outperform	$73.50	+28.19%
12/8/2025	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	John Eade Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
9/17/2025	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kerry Holford Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold ➝ Buy
9/16/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Neutral ➝ Buy
8/22/2025	Dbs Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong Sell ➝ Hold
8/13/2025	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Underperform ➝ Neutral
8/5/2025	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Weston Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/30/2025	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Emily Field Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight
4/17/2025	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Seamus Fernandez Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
3/3/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold
11/6/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Overweight	$160.00 ➝ $160.00	+49.39%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 11:29 PM ET.

Should I Buy Novo Nordisk A/S Stock? NVO Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, August 4, 2026. Please send any questions or comments about these Novo Nordisk A/S pros and cons to contact@marketbeat.com.

Novo Nordisk A/S
Bull Case

Here are some ways that investors could benefit from investing in Novo Nordisk:

Recent earnings per share (EPS) of $1.03 indicates strong profitability, showcasing the company's ability to generate earnings relative to its share price.
The company reported a substantial revenue of $10.85 billion for the quarter, reflecting robust sales performance and market demand for its products.
With a return on equity of over 63%, Novo Nordisk demonstrates effective management in generating profits from shareholders' equity, which is a positive indicator for potential investors.
Analysts forecast an EPS of 3.39 for the current year, suggesting expected growth in earnings, which could lead to an increase in stock value.
The current stock price is around $65.56, which is considered reasonable given the company's strong financial metrics and growth potential.

Novo Nordisk A/S
Bear Case

Investors should be bearish about investing in Novo Nordisk for these reasons:

Recent downgrades from several analysts, including a "strong sell" rating from Zacks Research, may indicate concerns about the company's future performance.
Weiss Ratings has reiterated a "sell" rating, suggesting that some analysts believe the stock may not perform well in the near term.
Despite a strong revenue report, the competitive landscape in the pharmaceutical industry, particularly in diabetes care, poses risks to market share and profitability.
Market sentiment appears mixed, with a consensus rating of "Hold" from analysts, indicating uncertainty about the stock's future performance.
Recent changes in institutional holdings, including significant sell-offs, could signal a lack of confidence among large investors in the company's prospects.

NVO Forecast - Frequently Asked Questions

According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for Novo Nordisk A/S is $65.56, with a high forecast of $175.00 and a low forecast of $40.00.

21 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 2 sell ratings, 14 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVO, but not buy additional shares or sell existing shares.

According to analysts, Novo Nordisk A/S's stock has a predicted upside of 47.40% based on their 12-month stock forecasts.

Over the previous 90 days, Novo Nordisk A/S's stock had 1 upgrade and 1 downgrade by analysts.

Novo Nordisk A/S has been rated by research analysts at Citigroup, HSBC, Nordea Equity Research, Weiss Ratings, and Zacks Research in the past 90 days.

Analysts like Novo Nordisk A/S less than other "healthcare" companies. The consensus rating score for Novo Nordisk A/S is 2.14 while the average consensus rating score for "healthcare" companies is 2.30. Learn more on how NVO compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Novo Nordisk A/S Recommendations

This page (NYSE:NVO) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novo Nordisk A/S (NVO) Stock Forecast & Price Target

Novo Nordisk A/S - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

NVO Analyst Ratings Over Time

NVO Analyst Recommendations By Month

NVO Price Targets by Month

Novo Nordisk A/S Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Novo Nordisk A/S Stock? NVO Pros and Cons Explained

Novo Nordisk A/S
Bull Case

Novo Nordisk A/S
Bear Case

NVO Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Novo Nordisk A/S Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novo Nordisk A/S (NVO) Stock Forecast & Price Target

Novo Nordisk A/S - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

NVO Analyst Ratings Over Time

NVO Analyst Recommendations By Month

NVO Price Targets by Month

Novo Nordisk A/S Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Novo Nordisk A/S Stock? NVO Pros and Cons Explained

Novo Nordisk A/S Bull Case

Novo Nordisk A/S Bear Case

NVO Forecast - Frequently Asked Questions

What is Novo Nordisk A/S's forecast for 2026?

Should I buy or sell Novo Nordisk A/S stock right now?

Does Novo Nordisk A/S's stock price have much upside?

Has Novo Nordisk A/S been upgraded or downgraded by Wall Street analysts recently?

What analysts cover Novo Nordisk A/S?

Do Wall Street analysts like Novo Nordisk A/S more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Novo Nordisk A/S Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Novo Nordisk A/S
Bull Case

Novo Nordisk A/S
Bear Case